EP Patent

EP0464845A1 — Pyrrole derivatives

Assigned to Shionogi and Co Ltd · Expires 1992-01-08 · 34y expired

What this patent protects

The compounds of the present invention inhibit the HMG-CoA reductase, and subsequently suppress the synthesis of cholesterol. And they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.

USPTO Abstract

The compounds of the present invention inhibit the HMG-CoA reductase, and subsequently suppress the synthesis of cholesterol. And they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP0464845A1
Jurisdiction
EP
Classification
Expires
1992-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Shionogi and Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.